STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
STO · EGTX.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Egetis Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Egetis Therapeutics AB (publ)’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -SEK 0.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Egetis Therapeutics AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:36 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 14.50M+107.14% vs estimate |
| Q1 2025 | Apr 30, 2025 | -SEK 0.17+27.66% vs estimate | SEK 12.70M0.0% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | -SEK 0.310.0% vs estimate | SEK 10.80M-29.41% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -SEK 0.300.0% vs estimate | SEK 9.40M-39.94% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
SEK 341.60+SEK 2.80 (+0.83%)
Sectra AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
SEK 279.50+SEK 2.00 (+0.72%)
Medicover AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
SEK 670.00SEK 0.00 (0.0%)
Camurus AB’s quoted price sits in the upper half of its reported 52-week range, 5.63% below the high.
SEK 9.90+SEK 0.40 (+4.21%)
Vicore Pharma Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 45.72% below the high.
SEK 68.30+SEK 0.40 (+0.59%)
Infant Bacterial Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 19.55% below the high.
SEK 1.00+SEK 0.02 (+2.45%)
Diamyd Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 94.38% below the high.
